

DAFTAR PUSTAKA

1. Setiati S, Alwi I, Sudoyo AW, Simadibrata MK, Setiyohadi BSA. Immunopatogenesis lupus eritematosus sistemik. Dalam: Setiati S, Alwi I, Sudoyo AW, Simadibrata MK, Setiyohadi B, Syam AF, penyunting. Buku Ajar Ilmu Penyakit Dalam. Edisi ke-6. Jakarta: Interna Publishing; 2014:3331-45.
2. Rahmadi AR, Burahman H, Ghassani NG, Wachjudi RG. B-Cell Activating Factor Profile and Quality of Life in Systemic Lupus Erythematosus Patients. *Indones J Rheumatol*. 2022;14:640–5.
3. Tian J, Zhang D, Yao X, Huang Y, Lu Q. Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study. *Ann Rheum Dis*. 2023;82:351–6.
4. Yuliasih. Perkembangan Patogenesis dan Tata Laksana Systemic Lupus Erythematosus. Surabaya: Airlangga University Press; 2020.
5. Pathak S, Mohan C. Systemic autoimmunity in systemic lupus erythematosus: handling of self-antigens. *Arthritis Res Ther*. 2011;13:1–9.
6. Crow MK. Etiology and pathogenesis of systemic lupus erythematosus. Dalam: Wallace DJ, Hahn BH, penyunting. *Dubois' Lupus Erythematosus and Related Syndromes*. Edisi ke-9. Philadelphia: Elsevier; 2019: 25–40.
7. Miguel B, Celeste M, Cruz MT. Pathogen strategies to evade innate immune response: a signaling point of view. *Protein Kinases*. Rijeka: InTech; 2012:123–64.
8. Guerra SG, Vyse TJ, Cunninghame Graham DS. The genetics of lupus: a functional perspective. *Arthritis Res Ther*. 2012;14(3):211.
9. Hahn BH. Systemic lupus erythematosus. Dalam: Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J, penyunting. *Harrison's Principles of Internal Medicine*. Edisi ke-20. New York: McGraw-Hill; 2018:2515–26.
10. Parodis I, Stockfelt M, Sjöwall C. B cell therapy in systemic lupus erythematosus: from rationale to clinical practice. *Front Med*. 2020;7:1–11.
11. Lumen Learning. B lymphocytes and humoral immunity. *Microbiology*.

- Pressbooks; 2020. Tersedia dari: <https://courses.lumenlearning.com/suny-microbiology/chapter/b-lymphocytes-and-humoral-immunity/>.
12. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. *Nat Rev Rheumatol*. 2014;10(6):365–73.
 13. Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. *Arthritis Rheum*. 2012;64(7):2328–37.
 14. Jacob CO, Yu N, Guo S, Jacob N, Quinn WJ 3rd, Sindhava V, et al. Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor. *Arthritis Rheum*. 2013;65(4):1043–54.
 15. Petri MA, van Vollenhoven RF, Buyon J, Levy RA, Navarra SV, Cervera R, et al. Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. *Arthritis Rheum*. 2013;65(8):2143–53.
 16. Petri M, Stohl W, Chatham W, McCune WJ, Chevrier M, Ryel J, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. *Arthritis Rheum*. 2008;58(8):2453–9.
 17. Salazar-Camarena DC, Ortiz-Lazareno PC, Cruz A, Oregon-Romero E, Machado-Contreras JR, Muñoz-Valle JF, et al. Association of BAFF, APRIL serum levels, BAFF-R, TACI and BCMA expression on peripheral B-cell subsets with clinical manifestations in systemic lupus erythematosus. *Lupus*. 2015;25(6):582–92.
 18. Durcan L, Petri M. Why targeted therapies are necessary for systemic lupus erythematosus. *Lupus*. 2016;25(10):1070–9.
 19. Fanouriakis A, Kostopoulou M, Andersen J, Aringer M, Arnaud L, Bae SC, et al. EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. *Ann Rheum Dis*. 2024;83(1):15–29.
 20. Roth DA, Thompson A, Tang Y, Hammer AE, Molta CT, Gordon D. Elevated BLYS levels in patients with systemic lupus erythematosus: associated factors and responses to belimumab. *Lupus*. 2016;25(4):346–54.

21. Gordon C, Wofsy D, Wax S, Li Y, Pena Rossi C, Isenberg D. Post hoc analysis of the Phase II/III APRIL-SLE study: association between response to atacicept and serum biomarkers including BLyS and APRIL. *Arthritis Rheumatol.* 2017;69(1):122–30.
22. Sumariyono, Kalim H, Setyohadi B, Hidayat R, Najirman, Hamikoyo L, et al. Diagnosis dan pengelolaan SLE. Rekomendasi Perhimpunan Reumatologi Indonesia: Diagnosis dan Pengelolaan Lupus Eritematosus Sistemik. 2019;1–129.
23. Gergianaki I, Bortoluzzi A, Bertsias G. Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. *Best Pract Res Clin Rheumatol.* 2018;32(2):188–205.
24. Amelia R, Wasilah F, Suraya N. Correlation of platelet to lymphocyte ratio and C-reactive protein to albumin ratio with MEX-SLEDAI scores in patients with systemic lupus erythematosus. *Althea Med J.* 2024;11(2):183–7.
25. Vitri RY, Wachjudi RG, Ghassani NG, Hamijoyo L. Correlation of B-cell-activating factor levels and disease activity in systemic lupus erythematosus patients. *Indian J Rheumatol.* 2021;16(1):13–7.
26. Barber MRW, Drenkard C, Falasinnu T, Hoi A, Mak A, Kow NY, et al. Global epidemiology of systemic lupus erythematosus. *Nat Rev Rheumatol.* 2021;17(9):515–32.
27. Stojan G, Petri M. Epidemiology of systemic lupus erythematosus: an update. *Curr Opin Rheumatol.* 2018;30(2):144–50.
28. Rees F, Doherty M, Grainge MJ, Lanyon P, Zhang W. The worldwide incidence and prevalence of systemic lupus erythematosus: a systematic review of epidemiological studies. *Rheumatology (UK).* 2017;56(11):1945–61.
29. Tanaka Y, O'Neill S, Li M, Tsai IC, Yang YW. Systemic lupus erythematosus: targeted literature review of the epidemiology, current treatment, and disease burden in the Asia Pacific region. *Arthritis Care Res (Hoboken).* 2022;74(2):187–98.
30. Leong PY, Huang JY, Chiou JY, Bai YC, Wei JCC. The prevalence and

- incidence of systemic lupus erythematosus in Taiwan: a nationwide population-based study. *Sci Rep*. 2021;11(1):1–8.
31. Pusat Data dan Informasi Kementerian Kesehatan RI. Situasi lupus di Indonesia. Pusat Data dan Informasi Kementerian Kesehatan RI; 2017:1–6.
 32. Perhimpunan Reumatologi Indonesia. Rekomendasi perhimpunan reumatologi indonesia untuk diagnosis dan pengelolaan lupus eritematosus sistemik. Jakarta: Perhimpunan Reumatologi Indonesia; 2019.
 33. Hamijoyo L, Candrianita S, Rahmadi AR, Dewi S, Darmawan G, Suryajaya BS, et al. The clinical characteristics of systemic lupus erythematosus patients in Indonesia: a cohort registry from an Indonesia-based tertiary referral hospital. *Lupus*. 2019;28(13):1604–9.
 34. Leffler J, Bengtsson AA, Blom AM. The complement system in systemic lupus erythematosus: an update. *Ann Rheum Dis*. 2014;73(9):1601–6.
 35. Bertsias B, Fanouriakis A. Treatment of systemic lupus erythematosus. In: *Advances in the Therapy of Autoimmune Diseases*. 2017.
 36. Hedrich CM. Epigenetics in SLE. *Curr Rheumatol Rep*. 2017;19(9):1–10.
 37. Jung CR, Chung WT, Chen WT, Lee RY, Hwang BF. Long-term exposure to traffic-related air pollution and systemic lupus erythematosus in Taiwan: a cohort study. *Sci Total Environ*. 2019;668:342–9.
 38. Rönnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease. *Lupus Sci Med*. 2019;6(1):1–11.
 39. Grech P, Khamashta MA. Targeted therapies in systemic lupus erythematosus. *Lupus*. 2018;27(6):978–86.
 40. Yuliasih. Perkembangan patogenesis dan tata laksana systemic lupus erythematosus. *J Univ Airlangga*. 2020;4(1):38–54.
 41. Idborg H, Oke V. Cytokines as biomarkers in systemic lupus erythematosus: value for diagnosis and drug therapy. *Int J Mol Sci*. 2021;22(3):1–15.
 42. Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. *Arthritis Rheum*. 2010;62(1):222–33.

43. Pieper K, Grimbacher B, Eibel H. B-cell biology and development. *J Allergy Clin Immunol.* 2013;131(4):959–71.
44. Durcan L, Petri M. Why targeted therapies are necessary for systemic lupus erythematosus. *Lupus.* 2017;25(9):1070–9.
45. Zou YR, Grimaldi C, Diamond B. B cells. Tenth edition. Elsevier Inc.; 2016.
46. Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: a tale of two B cell-targeting agents. *Front Med.* 2020;7(1):1–10.
47. Koyama T, Tsukamoto H, Miyagi Y, Himeji D, Otsuka J, Miyagawa H, et al. Raised serum APRIL levels in patients with systemic lupus erythematosus. *Ann Rheum Dis.* 2005;64(7):1065–7.
48. Hegazy M, Darwish H, Darweesh H, El-Shehaby A, Emad Y. Raised serum level of APRIL in patients with systemic lupus erythematosus: correlations with disease activity indices. *Clin Immunol.* 2010;135(1):118–24.
49. Salazar-Camarena DC, Palafox-Sánchez CA, Cruz A, Marín-Rosales M, Muñoz-Valle JF. Analysis of the receptor BCMA as a biomarker in systemic lupus erythematosus patients. *Clin Exp Rheumatol.* 2020;38(4):1–11.
50. Sari S, Cinar S, Yalcinkaya Y, Artim-Esen B, Ozluk Y, Gul A, et al. The relationship between serum A proliferation-inducing ligand and B-cell activating factor levels with disease activity and organ involvement in systemic lupus erythematosus. *Lupus.* 2022;31(5):555–64.
51. Szodoray P, Jonsson R. The BAFF/APRIL system in systemic autoimmune diseases with a special emphasis on Sjögren's syndrome. *Scand J Immunol.* 2005;62(5):421–8.
52. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, Habermann TM, et al. Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. *Blood.* 2004;104(8):2247–53.
53. Novak AJ, Bram RJ, Kay NE, Jelinek DF. Aberrant expression of B-lymphocyte stimulator by B chronic lymphocytic leukemia cells: a mechanism for survival. *Blood.* 2002;100(8):2973–9.
54. Ahn S. Role of B cells in common variable immune deficiency. *Expert Rev*

- Clin Immunol. 2009;5(5):557–64.
55. Borhis G, Trovato M, Chaoul N, Ibrahim HM, Richard Y. B-cell-activating factor and the B-cell compartment in HIV/SIV infection. *Front Immunol.* 2017;8:1338.
 56. Lendak DF, Mihajlović DM, Novakov-Mikić AS, Mitić IM, Boban JM, Brkić SV. The role of TNF- α superfamily members in immunopathogenesis of sepsis. *Cytokine.* 2018;111:125–30.
 57. Sanchez-Niño MD, Ortiz A. That obscure object of desire: in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians. *Nephrol Dial Transplant.* 2015;30(3):394–400.
 58. Nixon A, Ogden L, Woywodt A, Dhaygude A. Infectious complications of rituximab therapy in renal disease. *Clin Kidney J.* 2017;10(4):455–60.
 59. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Infections in the use of biologic therapies for autoimmune diseases. *Int J Infect Dis.* 2015;34:22–30.
 60. Samotij D, Reich A. Biologics in the treatment of lupus erythematosus: a critical literature review. *Biomed Res Int.* 2019;8142368.
 61. Huang SP, Snedecor SJ, Nanji S, Lloyd E. Real-world effectiveness of belimumab in systemic lupus erythematosus: a systematic literature review. *Rheumatol Ther.* 2022;9(3):975–91.
 62. Carter LM, Isenberg DA, Ehrenstein MR. Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. *Arthritis Rheum.* 2013;65(10):2672–9.
 63. Isenberg D, Gordon C, Licu D, Copt S, Rossi CP, Wofsy D. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). *Ann Rheum Dis.* 2015;74(11):2006–15.
 64. Fava A, Petri M. SLE: diagnosis and clinical management. *Physiol Behav.* 2020;176(1):139–48.
 65. Galarza-Maldonado C, Kourilovitch MR, Molineros JE, Cardiel MH, Zurita L, Soroka NF, et al. The administration of low doses of rituximab followed

- by hydroxychloroquine, prednisone and low doses of mycophenolate mofetil is an effective therapy in Latin American patients with active systemic lupus erythematosus. *Autoimmun Rev.* 2010;10(2):108–11.
66. Kurniawan RE. Perbedaan kadar glikoprotein P serum dan jumlah limfosit antara pasien lupus eritematosus sistemik aktif dan tidak aktif yang mendapat terapi metilprednisolon. *Bagian Ilmu Penyakit Dalam FK UNAND*; 2019:45–6.
 67. Rezazadeh M, Jokar MH, Aghili SM, Mirfeizi Z, Mahmoudi M, Morovatdar N, et al. Association between levels of serum and urinary B cell-activating factor and systemic lupus erythematosus disease activity. *Arch Rheumatol.* 2023;38(4):429–40.
 68. Eldin AB, Sayed S, Hegazy G, Shaker O. B-cell activating factor (BAFF) in systemic lupus erythematosus, rheumatoid arthritis, and Behçet's disease. *Turk J Rheumatol.* 2012;27(3):185–94.
 69. Santana-Sánchez P, Vaquero-García R, Legorreta-Haquet MV, Chávez-Sánchez L, Chávez-Rueda AK. Hormones and B-cell development in health and autoimmunity. *Front Immunol.* 2024;15:1–16.
 70. Khan A, Sawant T, Deen Z, Humayun W, Humayun Y. Systemic lupus erythematosus in the elderly that debuts with an organic manifestation of lupus nephritis. *Cureus.* 2022;14(8):e28613.
 71. Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. *Arthritis Res Ther.* 2015;17:1–10.
 72. Mahmoud K, Zayat A, Vital EM. Musculoskeletal manifestations of systemic lupus erythematosus. *Curr Opin Rheumatol.* 2017;29:486–92.
 73. Anders HJ, Saxena R, Zhao MH, Parodis I, Salmon JE, Mohan C. Lupus nephritis. *Nat Rev Dis Prim.* 2020;6.
 74. Ruiz-Irastorza G, Khamashta M. Cardiopulmonary disease in SLE. In: Dubois' *Lupus Erythematosus and Related Syndromes*. 8th ed. Elsevier Inc.; 2013:473–85.
 75. Liang Y, Leng RX, Pan HF, Ye DQ. The prevalence and risk factors for serositis in patients with systemic lupus erythematosus: a cross-sectional study. *Rheumatol Int.* 2017;37:305–11.

76. Karpouzas GA. Hematologic and lymphoid abnormalities in SLE. In: Dubois' Lupus Erythematosus and Related Syndromes. Elsevier Inc.; 2018:473–85.
77. Bashal F. Hematological disorders in patients with systemic lupus erythematosus. *Open Rheumatol J*. 2013;7:87–95.
78. Putra SD, Ardisasmita MN, Hamijoyo L. Neuropsychiatric manifestation screening among systemic lupus erythematosus patients in Hasan Sadikin General Hospital Bandung. *Indones J Rheumatol*. 2018;9:18–22.
79. Schwartz N, Stock AD, Putterman C. Neuropsychiatric lupus: new mechanistic insights and future treatment directions. *Nat Rev Rheumatol*. 2019.
80. Gordon C, Amissah-Arthur MB, Gayed M, Brown S, Bruce IN, D'Cruz D, et al. Comment on: The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: reply. *Rheumatology (Oxford)*. 2018;57:1502–3.
81. Costedoat-Chalumeau N, Dunogu   B, Leroux G, Morel N, Jallouli M, Le Guern V, et al. A critical review of the effects of hydroxychloroquine and chloroquine on the eye. *Clin Rev Allergy Immunol*. 2015;49(3):317–26.
82. Saavedra M  , S  nchez A, Morales S,   ngeles U, Jara LJ. Azathioprine during pregnancy in systemic lupus erythematosus patients is not associated with poor fetal outcome. *Clin Rheumatol*. 2015;34(7):1211–6.
83. Conti F, Ceccarelli F, Perricone C, Massaro L, Cipriano E, Pacucci VA, et al. Mycophenolate mofetil in systemic lupus erythematosus: results from a retrospective study in a large monocentric cohort and review of the literature. *Immunol Res*. 2014;60(2-3):270–6.

